Volociximab

Drug Profile

Volociximab

Alternative Names: Anti-α5β1 integrin antibody; Eos 200-4; M 200

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma
  • Developer Abbott Biotherapeutics Corp; Biogen Idec; National Cancer Institute (USA); OphthoTech Corporation; PDL BioPharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Integrin alpha 5 beta 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Intestinal cancer; Non-small cell lung cancer; Peritoneal cancer
  • Discontinued Malignant melanoma; Pancreatic cancer; Renal cell carcinoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in USA (Intravitreous, Injection)
  • 24 Jan 2013 Discontinued - Phase-II for Ovarian cancer (monotherapy, second-line) in USA (IV)
  • 24 Jan 2013 Discontinued - Phase-II for Ovarian cancer (monotherapy, second-line) in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top